Stephen Fry, MD
Gastroenterology · Kingsport, TNNPI 1750382982
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 41.1% of the total.
Across 329 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- AbbVie$479
- Daiichi Sankyo Inc.$358
- Takeda Pharmaceuticals U.S.A., Inc.$333
- Sanofi$276
- Johnson & Johnson$253
- plus $1K from 19 others
Across 62 payments — averaging $6641.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Capsovision, Inc.$168K
- Genentech, Inc.$134K
- Pfizer$41K
- Eli Lilly$31K
- Takeda Pharmaceuticals U.S.A., Inc.$22K
- Braintree Laboratories, Inc.$17K
What the payments were for
- Food & beverage$5,27599%
- Education$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 157 | $2,180 |
| AbbVie(2 entities) | 27 | $479 |
| Daiichi Sankyo Inc. | 15 | $358 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $333 |
| Sanofi | 14 | $276 |
| Johnson & Johnson | 13 | $253 |
| Gilead | 16 | $237 |
| Bristol Myers Squibb | 12 | $196 |
| Pfizer | 9 | $159 |
| Regeneron Healthcare Solutions, Inc. | 5 | $115 |
| Intercept Pharmaceuticals, Inc. | 6 | $95 |
| Ardelyx, Inc. | 5 | $95 |
| Phathom Pharmaceuticals, Inc. | 4 | $86 |
| Celltrion USA Inc. | 3 | $64 |
| Aimmune Therapeutics, Inc. | 3 | $62 |
| Nestle Healthcare Nutrition Inc. | 4 | $61 |
| Braintree Laboratories, Inc. | 3 | $52 |
| Merck | 3 | $48 |
| Boston Scientific | 2 | $41 |
| Romark Laboratories, LC | 3 | $36 |
| UCB, Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| QOL Medical, LLC | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
How this compares
$5,304 in reported general payments places this provider in the 60th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 15 | $96,005 |
| XifaxanRifaximin | 24 | $81,361 |
| LinzessLinaclotide | 82 | $64,710 |
| VoqueznaVonoprazan Fumarate | 27 | $18,492 |
| Dexlansoprazole DrDexlansoprazole | 49 | $9,932 |
| Dicyclomine Hcl | 313 | $7,324 |
| MotegrityPrucalopride Succinate | 11 | $5,555 |
| Omeprazole | 253 | $5,410 |
| Mesalamine ErMesalamine | 48 | $5,376 |
| Pantoprazole Sodium | 552 | $5,156 |
| Mercaptopurine | 28 | $3,786 |
| Esomeprazole Magnesium | 80 | $3,656 |
| Ursodiol | 35 | $3,077 |
| Mesalamine | 15 | $2,858 |
| Colestipol Hcl | 44 | $2,658 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $2,180 | $81,36124 claims |
| AbbVieLinzess | $479 | $64,71082 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $86 | $18,49227 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $333 | $5,55511 claims |
| Braintree Laboratories, Inc.Suflave | $52 | $2,14017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Kingsport
- Jeffrey FenyvesKingsport$14K
- David SchwartzNashville$1.3M
- Ziad YounesGermantown$1M
- Dawn Borromeo BeaulieuNashville$421K
- Satheesh NairMemphis$349K
- Colin HowdenMemphis$291K
- Sara HorstNashville$246K
- Raj NarayaniKnoxville$204K
- Chakradhar ReddyJohnson City$161K
- Leonard BaidooMemphis$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.